Low rates of hepatitis B virus screening at the onset of chemotherapy.
about
Management of patients with hepatitis B who require immunosuppressive therapyRecent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder systemRisk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral ProphylaxisHepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.Low level of hepatitis B virus screening among patients receiving chemotherapyInvited Commentary: Screening for hepatitis B in the immigrant population and individuals who are in need of immunosuppressive drug therapy.Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab.Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver DiseasesHepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy.Prevention and management of hepatitis B virus reactivation in cancer patients.Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan.Gastroenterologists Have Suboptimal Hepatitis B Virus Screening Rates in Patients Receiving Immunosuppressive Therapy.Screening for viral hepatitis prior to rituximab chemotherapy.Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area.Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project.Relationships between hepatitis B infection status and liver dysfunction after chemotherapy of lung cancer patients in mainland China.Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network.Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy.Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.Infliximab and occult hepatitis B infection: to treat or not to treat?A Community-Based Randomized Trial of Hepatitis B Screening Among High-Risk Vietnamese Americans.
P2860
Q26853490-BFB90DF6-19A0-4C30-851C-29A0D641819EQ33872389-1B3C95CC-5C09-4477-939D-69DF903C3CCDQ35037621-075F6282-B0B8-4AF1-B334-010B936BBB36Q35057889-C9365F8B-66D3-4085-87C6-5248472774FCQ35746079-CCEECFFE-4C44-40F4-9054-DDFB0A1FE2BFQ35771194-0547ECBE-BC6B-473D-8007-AAB71F14B00AQ35991451-8E756DDC-D9A0-47B3-8DA2-86623614F7FCQ36058287-8AF8418B-F942-4C42-B380-3818067CE152Q36326450-FAB1BD29-4A79-417C-BE37-A77CCB14162CQ36803202-14D69066-DE11-4915-825A-9C0662DB72E2Q36958944-D9832FCA-C092-4FC9-A165-199AAF354B1EQ38688782-94B3B3EF-955B-43F8-A993-AD361155F716Q38778109-004A1047-B5DB-4FD7-8FF4-820353CBE75FQ39711189-CE16C284-B9FF-4973-9BCE-DEA775D65A8CQ39906266-8349EFD8-611B-4662-B1A5-911ED30EA9FEQ40993578-859D09D4-DFCE-4C31-9FB6-50F52B668CFEQ41186450-759D4EF7-EB10-4E87-84CC-3A5F6D33CCECQ42234350-854D9CFD-DC1C-4632-8235-18F2CB5F4D69Q44366710-A95480B9-A243-4D61-A75D-BE62B62D5121Q45324215-5D269413-D66C-433C-A1D5-4D2CB5768590Q45324587-012DDED6-9B13-466F-916D-EDAE8E517C01Q50190669-3367F29A-909E-47C3-8FBA-7BB3EE1A3341Q51866366-5E7BE3BF-5E09-4941-8ACD-25CEA363F134Q53124322-2DDC99CD-F4DE-4E60-9261-8C635989312E
P2860
Low rates of hepatitis B virus screening at the onset of chemotherapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Low rates of hepatitis B virus screening at the onset of chemotherapy.
@ast
Low rates of hepatitis B virus screening at the onset of chemotherapy.
@en
type
label
Low rates of hepatitis B virus screening at the onset of chemotherapy.
@ast
Low rates of hepatitis B virus screening at the onset of chemotherapy.
@en
prefLabel
Low rates of hepatitis B virus screening at the onset of chemotherapy.
@ast
Low rates of hepatitis B virus screening at the onset of chemotherapy.
@en
P2093
P2860
P356
P1476
Low rates of hepatitis B virus screening at the onset of chemotherapy
@en
P2093
Hong Zhang
John M Vierling
Lincy S Lal
Maria E Suarez-Almazor
Mark J Routbort
Michael A Kallen
Michael J Fisch
P2860
P356
10.1200/JOP.2011.000450
P407
P577
2012-06-12T00:00:00Z